Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder
NCT06633016 is registered in ClinicalTrials.gov with Autobahn Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder
- Lead sponsor
- Autobahn Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 20, 2024
- Completion date
- June 30, 2026
- Enrollment
- 230 (estimated)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.